Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-1503 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ZL-1503: Participants will receive single ascending doses of ZL-1503 | EXPERIMENTAL | Part A: Single Ascending Dose (SAD) |
| ZL-1503: Participants will receive multiple ascending doses of ZL-1503 | EXPERIMENTAL | Part B: Multiple Ascending Dose (MAD) |
| Name | Type | Description |
|---|---|---|
| ZL-1503 | DRUG | Healthy volunteers will receive ZL-1503. |
| Placebo | DRUG | Healthy volunteers will receive placebo. |
Inclusion Criteria: * Part A: 1. Healthy male and female volunteers, 18-65 years of age 2. Body mass index (BMI) between ≥ 18.5 and \< 32.5 kg/m2 3. Negative pregnancy tests for women of childbearing potential. * Part B: 1. 18-65 years of age; 2. BMI between ≥18.5 and \<40.0 kg/m2 3. ...
Top 20 of 26 competitors
ZL-1503 is an investigational small molecule being developed by Zai Lab Limited for atopic dermatitis. It is a Phase 1 asset in dermatology and has not been approved for any use. It is being studied in healthy volunteers and in participants with moderate to severe atopic dermatitis.
ZL-1503 is being developed for atopic dermatitis, a chronic inflammatory skin condition. The clinical program targets participants with moderate to severe disease. Because ZL-1503 is still in Phase 1 development, it is investigational and is not yet available as a treatment outside of clinical trials.
ZL-1503 targets IL-13 and IL-31R, which are cytokine receptors. IL-13 is a cytokine involved in type 2 inflammation, and IL-31R is the receptor for IL-31, a cytokine linked to itch signaling. By acting on both targets, ZL-1503 is designed as a small molecule with a dual mechanism.
Zai Lab Limited is developing ZL-1503. Zai Lab is a biopharmaceutical company that trades under the ticker ZLAB. The company is running the ZL-1503 program in dermatology, with atopic dermatitis as the lead indication in its clinical development plan.
ZL-1503 is in Phase 1 development. It is investigational and has not been approved by the FDA or any other regulatory agency. The ongoing study is a Phase 1/1b trial, and no trials of ZL-1503 have been completed to date.
ZL-1503 is being studied in one active clinical trial, NCT07235384, titled a Phase 1/1b study to evaluate safety, tolerability and pharmacokinetics of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis. The trial is recruiting, is randomized, double blind and controlled, and plans to enroll 84 participants in Australia, China and New Zealand.